Orexigen Therapeutics Inc. and Investors Laud Obesity Drug Prospects

Orexigen Therapeutics Inc. and Investors Laud Obesity Drug Prospects

Investors are singing the praises for Orexigen Therapeutics, Inc. This morning as the company announced a resounding success concerning the prospects of an obesity drug currently under development. Contrave is intended to be a treatment for poorly managed obesity. The drug is a combination of two medications. Buproprion, which is as fun to say as […]